RxDoctor Payments Data

Theresa Meltz, PA

Medical · Hudson, NYNPI 1083654297

Payments from drug & device makers

$5,963in general payments, 2019–2025

Across 322 payments — averaging $18.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$878
  • AbbVie$571
  • AstraZeneca$544
  • Boehringer Ingelheim$527
  • Pfizer$426
  • Novo Nordisk$415
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,963100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,963 in reported general payments places this provider in the 90th percentile of 2,395 medical providers in New York.

See all medical providers in New York

Medicare billing

Part B allowed, 2024
$33,677
Medicare patients
225
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$92,685
FarxigaDapagliflozin Propanediol100$86,478
OzempicSemaglutide71$80,972
JardianceEmpagliflozin63$68,199
JanuviaSitagliptin Phosphate33$49,669
TrulicityDulaglutide33$37,509
RybelsusSemaglutide26$26,680
XareltoRivaroxaban17$22,647
TradjentaLinagliptin11$15,332
Breo ElliptaFluticasone/Vilanterol16$11,088
Atorvastatin Calcium631$5,908
Albuterol Sulfate HfaAlbuterol Sulfate127$5,688
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,321
Omeprazole393$4,668
Rosuvastatin Calcium209$4,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$415$107,65397 claims
PfizerEliquis$426$92,68580 claims
AstraZenecaFarxiga$544$86,478100 claims
Boehringer IngelheimJardiance, Tradjenta$527$83,53174 claims
MerckJanuvia$25$49,66933 claims
Lilly USA, LLCTrulicity$92$37,50933 claims
Johnson & JohnsonXarelto$101$22,64717 claims
GSKBreo Ellipta$878$11,08816 claims
AbbVieSynthroid$571$1,91325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,395 medical providers in New York.

Other medical in Hudson

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →